As bemarituzumab is currently the most promising direct therapy for FGFR2-overexpressed GC, we restate that, as part of the inclusion criteria defined in the FIGHT (NCT03694522) [79] and FORTITUDE-101 (NCT05052801) (20) trials, FGFR2 overexpression by IHC is defined as moderate-to-strong (2+/3+) membranous staining in ≥10% of tumor cells. Here, FGFR2 is linked to neoplasm.